Brain Injury
Conditions
Keywords
Sevoflurane, Brain injury, Intra cranial pressure, Sedation, Brain injury with initial Glasgow score less than 9
Brief summary
Main purpose of the study is to evaluate the effect of sevoflurane on intra cranial pressure (ICP) after traumatic brain injury. Patients admitted for traumatic brain injury equipped with ICP measurement will be sedated with sevoflurane via the Anaconda device during 12 hours. Sedation will be controlled with BIS.
Detailed description
Sedation is most of the time required for ICP management after traumatic brain injury. Sevoflurane, an inhaled anaesthetic drug is commonly used in operatory room. Thanks to a new device, the Anaconda, it now can be applied to intensive care patients. His advantages a rapid elimination after administration stops, which can allow an early neurologic evaluation, very important for traumatic brain injury patients.We will study the effect of sevoflurane administration on ICP of TBI patients. Patients admitted for severe TBI (Glasgow come scale \< 8), equipped with ICP sensor, elder than 18 years old will be include. A sedation with sevoflurane will be administrated during 12 hours instead of classical intra venous sedation with midazolam, depending on BIS score. ICP evolution will be characterised in success if \< 30 mmHg or failure if ≥ 30 mmHg.6 patients will be included for the first phase. The study will be stopped if the failures are ≥ 2. Otherwise, 27 patients will be included. Study will be stopped if failures number ≥ 5 before the end if the inclusion period.
Interventions
DRUG1: Sevoflurane
Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics.
Sponsors
Ministry of Health, France
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* severe traumatic brain injury (glasgow \< 8) * age \> 18 * no surgery scheduled * sedation with midazolam and sufentanil * ICP sensor
Exclusion criteria
* external ventricular derivation * pregnancy * antecedent of malign hyperthermia * haemodynamic instability
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ICP evolution | ICP will be continuously recorded during the 12 hours of sedation with sevoflurane | patients where ICP increase more than 30 mmHg during more than 15 minutes will be characterized as failure. Patients whose ICP do not increase during the 12 hours of sedation with sevoflurane will be characterized as success. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sedation level | during the 12 hours of sedation with sevoflurane | sedation level will be evaluated with the measure of the Bispectral Index and the SAS sedation score. Proportion of time with BIS of 45-65% and SAS \<2, which are the objective of sedation level, will be recorded. |
| Haemodynamic tolerance | during the 12 hours of sedation with sevoflurane | invasive mean arterial pressure (MAP) will be continuously recorded. Hypotension is defined by a MAP less than 60 mmHg. |
| Malignant hyperthermia screening | during the 12 hours of sedation with sevoflurane | increase of eardrum temperature more than 39°C is considered as potential malignant hyperthermia |
Countries
France
Outcome results
None listed